BMEA (Biomea Fusion) Accounts Payable: $4.61 Mil (As of Mar. 2026)


BMEA Biomea Fusion Inc BMEA
30 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Accounts Payable?

Biomea Fusion BMEA 30 Accounts Payable is $4.61 Mil as of Mar. 2026. GuruFocus rates BMEA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Biomea Fusion's Accounts Payable for the quarter that ended in Mar. 2026 was $4.61 Mil.

Biomea Fusion's quarterly Accounts Payable declined from Sep. 2025 ($6.40 Mil) to Dec. 2025 ($3.23 Mil) but then increased from Dec. 2025 ($3.23 Mil) to Mar. 2026 ($4.61 Mil).

Biomea Fusion's annual Accounts Payable increased from Dec. 2023 ($6.85 Mil) to Dec. 2024 ($12.93 Mil) but then declined from Dec. 2024 ($12.93 Mil) to Dec. 2025 ($3.23 Mil).

Biomea Fusion Accounts Payable Related Terms

Biomea Fusion Accounts Payable Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion Accounts Payable Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 1.33 6.83 6.85 12.93 3.23

Biomea Fusion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.71 8.38 6.40 3.23 4.61
BMEA
30GF Score
Biomea Fusion Inc BMEA
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $4.61 Mil mean?
Biomea Fusion (BMEA) has a Accounts Payable of $4.61 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biomea Fusion and its competitors.
Is Biomea Fusion's Accounts Payable too high?
Biomea Fusion's current Accounts Payable is $4.61 Mil. Overall, Biomea Fusion has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Accounts Payable compare to ANIX and PMN?
Biomea Fusion's Accounts Payable of $4.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Biomea Fusion and its competitors. Biomea Fusion's current Accounts Payable is $4.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Accounts Payable of $4.61 Mil. The current Accounts Payable is $4.61 Mil. Biomea Fusion's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Accounts Payable is $4.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
30GF Score

Get the complete analysis for BMEA

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price